Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men

Exclusion Criteria

• •PUL
• •1. Active urinary tract infections, prostatitis, or interstitial cystitis.
• •2. Biopsy proven prostate, bladder, or urethral cancer.
• •The following patients must undergo prostate biopsy with a minimum of 12 cores and have a negative histopathology report to be enrolled in the study:
• •* Patients with digital rectal examination (DRE) findings suspicious for prostate cancer
• •* Patients with baseline PSA levels \> 10 ng/mL
• •* Patients with baseline PSA levels \>2.5 ng/mL and \< 10ng/mL AND free PSA \< 25% of total PSA Patients with cystoscopy findings suspicious for bladder cancer must undergo biopsy and have a negative histopathology report to be enrolled in the study
• •3. Significant median lobe enlargement.
• •4. Large prostates, volume \>80 g.
• •5. Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function (e.g. multiple sclerosis, Parkinson's disease, spinal cord injuries, etc.)
• •6. Urethral stricture, bladder neck contracture, sphincter abnormalities, bladder diverticulum, urinary obstruction due to causes other than BPH, or other potentially confounding bladder or urethral disease or condition
• •7. Urethral conditions that may prevent insertion of a rigid 20F cystoscope
• •8. Current urinary retention.
• •9. Acontractile detrusor.
• •10. Current gross hematuria
• •11. Known upper tract renal disease
• •12. Cystolithiasis
• •13. ASA \> 3 or severe medical debilitating condition
• •14. History of pelvic irradiation or radical pelvic surgery
• •15. Known allergy to nickel.
• •PAE
• •16. Active urinary tract infections, prostatitis, or interstitial cystitis.
• •17. Biopsy proven prostate, bladder, or urethral cancer.
• •The following patients must undergo prostate biopsy with a minimum of 12 cores and have a negative histopathology report to be enrolled in the study:
• •* Patients with digital rectal examination (DRE) findings suspicious for prostate cancer
• •* Patients with baseline PSA levels \> 10 ng/mL
• •* Patients with baseline PSA levels \>2.5 ng/mL and \< 10ng/mL AND free PSA \< 25% of total PSA Patients with cystoscopy findings suspicious for bladder cancer must undergo biopsy and have a negative histopathology report to be enrolled in the study
• •18. Unable to have CT angio of the prostate imaging
• •19. Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function (e.g. multiple sclerosis, Parkinson's disease, spinal cord injuries, etc.)
• •20. Urethral stricture, bladder neck contracture, sphincter abnormalities, bladder diverticulum, urinary obstruction due to causes other than BPH, or other potentially confounding bladder or urethral disease or condition
• •21. Acontractile detrusor.
• •22. Known upper tract renal disease
• •23. Cystolithiasis
• •24. Any known condition that limits catheter-based intervention or is a contraindication to embolization, such as intolerance to a vessel occlusion procedure or severe atherosclerosis. Known major iliac arterial occlusive disease
• •25. ASA \> 3 or severe medical debilitating condition
• •26. Baseline serum creatinine level \> 1.8 mg/dl
• •27. Previous rectal surgery other than hemorrhoidectomy, or history of rectal disease
• •28. History of pelvic irradiation or radical pelvic surgery
• •29. Allergy to iodinated contrast agents